The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis

PLoS One. 2016 Sep 8;11(9):e0162605. doi: 10.1371/journal.pone.0162605. eCollection 2016.

Abstract

Background: With the increased use of neoadjuvant chemotherapy (NAC) in breast cancer, the timing of sentinel lymph node biopsy (SLNB) has become increasingly important. In this study, we aimed to evaluate the feasibility and accuracy of SLNB for initially clinically node-negative breast cancer after NAC by conducting a systematic review and meta-analysis.

Methods: We searched PubMed, Embase, and the Cochrane Library from January 1, 1993 to November 30, 2015 for studies on initially clinically node-negative breast cancer patients who underwent SLNB after NAC followed by axillary lymph node dissection (ALND).

Results: A total of 1,456 patients from 16 studies were included in this review. The pooled identification rate (IR) for SLNB was 96% [95% confidence interval (CI): 95%-97%], and the false negative rate (FNR) was 6% (95% CI: 3%-8%). The pooled sensitivity, negative predictive value (NPV) and accuracy rate (AR) were 94% (95% CI: 92%-97%, I2 = 27.5%), 98% (95% CI: 98%-99%, I2 = 42.7%) and 99% (95% CI: 99%-100%, I2 = 32.6%), respectively. In the subgroup analysis, no significant differences were found in either the IR of an SLNB when different mapping methods were used (P = 0.180) or in the FNR between studies with and without immunohistochemistry (IHC) staining (P = 0.241).

Conclusion: Based on current evidence, SLNB is technically feasible and accurate enough for axillary staging in initially clinically node-negative breast cancer patients after NAC.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • False Negative Reactions
  • Feasibility Studies
  • Female
  • Humans
  • Lymph Nodes / pathology*
  • Lymphatic Metastasis / pathology
  • Neoadjuvant Therapy*
  • Predictive Value of Tests
  • Publication Bias
  • Sentinel Lymph Node Biopsy*

Grants and funding

This work was supported by the Key Research and Development Program of Shandong Province (no. 2015GSF118023, recipient: JL) and the Projects of Medical and Health Technology Development Program in Shandong Province (no. 2014WS0349, recipient: JL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.